Carla Magda Allan S Domingues1, Jennifer R Verani2, Ernesto Issac Montenegro Renoiner3, Maria Cristina de Cunto Brandileone4, Brendan Flannery5, Lucia Helena de Oliveira6, João Barberino Santos7, José Cássio de Moraes8. 1. National Immunization Program, Secretariat for Health Surveillance, Ministry of Health, Brasília, Brazil; Center for Tropical Medicine, University of Brasília, Brasília, Brazil. Electronic address: carla.domingues@saude.gov.br. 2. National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA. 3. National Immunization Program, Secretariat for Health Surveillance, Ministry of Health, Brasília, Brazil. 4. National Reference Laboratory for Meningitis and Pneumococcal Infections, Bacteriology Center, Adolfo Lutz Institute, Secretary of Health of the State of São Paulo, São Paulo, Brazil. 5. Pan American Health Organization, Brasília, Brazil. 6. Pan American Health Organization, Washington, DC, USA. 7. Center for Tropical Medicine, University of Brasília, Brasília, Brazil. 8. Department of Social Medicine, School of Medical Sciences of Santa Casa, São Paulo, Brazil.
Abstract
BACKGROUND: In March 2010, Brazil introduced the ten-valent pneumococcal conjugate vaccine (PCV10), which was licensed based on non-inferiority of immunological correlates of protection compared with the seven-valent vaccine. The schedule comprised three primary doses at ages 2 months, 4 months, and 6 months, and a booster dose at age 12 months. A single catch-up dose was offered for children aged 12-23 months at the time of introduction. We assessed PCV10 effectiveness against invasive pneumococcal disease in Brazilian children. METHODS: Invasive pneumococcal disease, defined as isolation of Streptococcus pneumoniae from blood, cerebrospinal fluid, or another normally sterile site, was identified in children age-eligible for at least one PCV10 dose through laboratory-based and hospital-based surveillance in ten states in Brazil from March 1, 2010, until Dec 31, 2012. We aimed to identify four age-matched and neighbourhood-matched controls for each case. We used conditional logistic regression and calculated PCV10 effectiveness as (1-adjusted matched odds ratio) × 100% for vaccine-type and vaccine-related serotypes (ie, in the same serogroup as a vaccine serotype). FINDINGS: In 316 cases (median age 13·2 months, range 2·6-53·1) and 1219 controls (13·3 months, 2·6-53·1), the adjusted effectiveness of an age-appropriate PCV10 schedule was 83·8% (95% CI 65·9-92·3) against vaccine serotypes, and 77·9% (41·0-91·7) against vaccine-related serotypes. Serotype-specific effectiveness was shown for the two most common vaccine serotypes-14 (87·7%, 60·8-96·1) and 6B (82·8%, 23·8-96·1)-and serotype 19A (82·2%, 10·7-96·4), a serotype related to vaccine serotype 19F. A single catch-up dose in children aged 12-23 months was effective against vaccine-type disease (68·0%, 17·6-87·6). No significant effectiveness was shown against non-vaccine serotypes for age-appropriate or catch-up schedules. INTERPRETATION: In the routine immunisation programme in Brazil, PCV10 prevents invasive disease caused by vaccine serotypes. PCV10 might provide cross-protection against some vaccine-related serotypes. FUNDING: Brazilian Ministry of Health, Pan-American Health Organization, and US Centers for Disease Control and Prevention.
BACKGROUND: In March 2010, Brazil introduced the ten-valent pneumococcal conjugate vaccine (PCV10), which was licensed based on non-inferiority of immunological correlates of protection compared with the seven-valent vaccine. The schedule comprised three primary doses at ages 2 months, 4 months, and 6 months, and a booster dose at age 12 months. A single catch-up dose was offered for children aged 12-23 months at the time of introduction. We assessed PCV10 effectiveness against invasive pneumococcal disease in Brazilian children. METHODS: Invasive pneumococcal disease, defined as isolation of Streptococcus pneumoniae from blood, cerebrospinal fluid, or another normally sterile site, was identified in children age-eligible for at least one PCV10 dose through laboratory-based and hospital-based surveillance in ten states in Brazil from March 1, 2010, until Dec 31, 2012. We aimed to identify four age-matched and neighbourhood-matched controls for each case. We used conditional logistic regression and calculated PCV10 effectiveness as (1-adjusted matched odds ratio) × 100% for vaccine-type and vaccine-related serotypes (ie, in the same serogroup as a vaccine serotype). FINDINGS: In 316 cases (median age 13·2 months, range 2·6-53·1) and 1219 controls (13·3 months, 2·6-53·1), the adjusted effectiveness of an age-appropriate PCV10 schedule was 83·8% (95% CI 65·9-92·3) against vaccine serotypes, and 77·9% (41·0-91·7) against vaccine-related serotypes. Serotype-specific effectiveness was shown for the two most common vaccine serotypes-14 (87·7%, 60·8-96·1) and 6B (82·8%, 23·8-96·1)-and serotype 19A (82·2%, 10·7-96·4), a serotype related to vaccine serotype 19F. A single catch-up dose in children aged 12-23 months was effective against vaccine-type disease (68·0%, 17·6-87·6). No significant effectiveness was shown against non-vaccine serotypes for age-appropriate or catch-up schedules. INTERPRETATION: In the routine immunisation programme in Brazil, PCV10 prevents invasive disease caused by vaccine serotypes. PCV10 might provide cross-protection against some vaccine-related serotypes. FUNDING: Brazilian Ministry of Health, Pan-American Health Organization, and US Centers for Disease Control and Prevention.
Authors: M C Brandileone; V S Vieira; S T Casagrande; R C Zanella; M L Guerra; S Bokermann; J C De Moraes; E R Baldacci; C B Chamone; M A Oliveira; D G De Matos; T M Arruda; M F Coelho; S M D'Avila; A R Dos Santos; J L Di Fabio Journal: Microb Drug Resist Date: 1997 Impact factor: 3.431
Authors: Cynthia G Whitney; Tamar Pilishvili; Monica M Farley; William Schaffner; Allen S Craig; Ruth Lynfield; Ann-Christine Nyquist; Kenneth A Gershman; Marietta Vazquez; Nancy M Bennett; Arthur Reingold; Ann Thomas; Mary P Glode; Elizabeth R Zell; James H Jorgensen; Bernard Beall; Anne Schuchat Journal: Lancet Date: 2006-10-28 Impact factor: 79.321
Authors: Maria-Cristina C Brandileone; Ana-Lucia S Sgambatti de Andrade; José-Luis Di Fabio; Maria-Luiza L S Guerra; Robert Austrian Journal: J Infect Dis Date: 2003-03-26 Impact factor: 5.226
Authors: Maria da Gloria S Carvalho; Maria Lucia Tondella; Karen McCaustland; Luciana Weidlich; Lesley McGee; Leonard W Mayer; Arnold Steigerwalt; Melissa Whaley; Richard R Facklam; Barry Fields; George Carlone; Edwin W Ades; Ron Dagan; Jacquelyn S Sampson Journal: J Clin Microbiol Date: 2007-05-30 Impact factor: 5.948
Authors: Katherine L O'Brien; Lara J Wolfson; James P Watt; Emily Henkle; Maria Deloria-Knoll; Natalie McCall; Ellen Lee; Kim Mulholland; Orin S Levine; Thomas Cherian Journal: Lancet Date: 2009-09-12 Impact factor: 79.321
Authors: Juliana Caierão; Paulina Hawkins; Fernando Hayashi Sant'anna; Gabriela Rosa da Cunha; Pedro Alves d'Azevedo; Lesley McGee; Cícero Dias Journal: PLoS One Date: 2014-10-30 Impact factor: 3.240
Authors: K Aaron Geno; Gwendolyn L Gilbert; Joon Young Song; Ian C Skovsted; Keith P Klugman; Christopher Jones; Helle B Konradsen; Moon H Nahm Journal: Clin Microbiol Rev Date: 2015-07 Impact factor: 26.132
Authors: M P Mott; J Caierão; G R Cunha; M M Del Maschi; K Pizzutti; P d'Azevedo; C A G Dias Journal: Epidemiol Infect Date: 2019-01 Impact factor: 2.451
Authors: Austen Chen; Beth Mann; Geli Gao; Richard Heath; Janice King; Jeff Maissoneuve; Mark Alderson; Andrea Tate; Susan K Hollingshead; Rodney K Tweten; David E Briles; Elaine I Tuomanen; James C Paton Journal: Clin Vaccine Immunol Date: 2015-08-05